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Greogry L. Moneta, MD, Section EditorPopulation-Based Study of Incidence and Outcome of Acute Aortic
Dissection and Premorbid Risk Factor Control: 10-Year Results
From the Oxford Vascular Study
Howard DPJ, Banerjee A, Fairhead JF, et al. Circulation 2013;127:2031-7.
Conclusions: Hospital-based registries likely underestimate not only
the incidence of acute aortic dissection but also its association with premor-
bid hypertension. The most signiﬁcant treatable condition leading to acute
aortic dissection remains uncontrolled hypertension.
Summary: Even with well-established treatment guidelines, acute
aortic dissection can have a high case fatality rate. However, little data on
risk factors, incidence, or outcome of acute aortic dissection are available,
and there is no prospective population-based study. Although abdominal
aortic aneurysm incidence of rupture appears to be declining (Darwood R
et al, J Vasc Surg 2012;56:8-13), trends with respect to acute aortic dissec-
tion are uncertain (Thrumurthy SG et al, BMJ 2012;344:d8290). The
authors note there have only been two studies of the epidemiology of aortic
dissection since 1980, and both were retrospective and used only routinely
collected diagnostic or mortality coding data. Neither study assessed pre-
morbid risk factors or functional outcome (Clouse WD et al, Mayo Clin
Proc 2004;79:176-80; and Olsson C et al, Circulation 2006;114:2611-8).
This study used the 92,728 patient population of Oxfordshire in the United
Kingdom to prospectively determine event rates, incidence, risk factors,
early case fatality, and long-term outcome of all cases of acute aortic dissec-
tion from 2002 to 2012. Data were collected as part of the Oxford Vascular
Study. Among 155 patients with 174 acute aortic events, there were 54
patients (31 men; mean age, 72.0 years) with 59 thoracoabdominal aortic
dissections (52 incident events: 6/100,000; 95% conﬁdence interval, 4-7)
comprising 37 Stanford type A and 15 Stanford type B. Of the patients
with type A incident events, 18 (48.6%) died before hospital assessment
(61.1% women). The 30-day fatality rate was 47.4% for patients with type
A dissections who survived to hospital admission and 13.3% for patients
with type B dissections. Subsequent 5-year survival rates were, however,
high (85.7% for type A; 83.3% for type B). Although 67.3% of patients
were taking antihypertensive drugs, 46.0% had at least one systolic BP
>180 mm Hg in their primary care records during the preceding 5 years.
The proportion of blood pressures in the hypertensive range (>140/90
mmHg) averaged 56.0%. Premorbid blood pressure in the type A dissection
patients was higher in those patients where the dissection was immediately
fatal than in those who survived to admission (mean/standard deviation
pre-event systolic blood pressure was 151.2 6 19.3 vs 137.9 6 17.9;
P < .001).
Comment: The data suggest that the incidence of acute aortic dissec-
tion is higher than previously reported. The authors speculate this is likely
due to more complete inclusion of deaths before hospital admission. If
one does the numbers in the report, it appears there are w44 ruptured
abdominal aortic aneurysms per year and 24 acute aortic dissections per
year in the Oxford population ofw93,000 patients. The Oxford population
is 94% Caucasian, whereas that of the United States is about 72.4% Cauca-
sian, and thus, the incidence rates of acute aortic events in this study are not
directly applicable to all populations. Nevertheless, the epidemiologic data
provided here allow one to estimate the burden of acute aortic events in
many regions of Europe, Australia, and the United States.
Cilostazol Reduces Angiographic Restenosis After Endovascular
Therapy for Femoropopliteal Lesions in the Sufﬁcient Treatment of
Peripheral Intervention by Cilostazol Study
Iida O, Yokoi H, Soga Y, et al., and the STOP-IC investigators. Circulation
2013;127:2307-15.
Conclusions: Cilostazol reduces angiographic restenosis for femoro-
popliteal lesions after percutaneous transluminal angioplasty with provi-
sional nitinol stenting.
Summary: Use of nitinol stents has improved long-term outcomes of
endovascular therapy for femoropopliteal lesions compared with balloon
angioplasty alone (Schillinger M et al, N Engl J Med 2006;354:1879-88;
and Laird JR et al, Circ Cardiovasc Interv 2010;3:267-76). However,
even with the use of stents, there remains a 20% to 50% incidence of reste-
nosis at 1 year. The present study was designed to determine, usingangiographic follow-up, whether treatment with cilostazol reduces resteno-
sis at 12 months after percutaneous transluminal angioplasty with provi-
sional nitinol stenting. The Sufﬁcient Treatment of Peripheral
Intervention by Cilostazol study enrolled 200 patients with femoropopliteal
lesions. Patients were treated from March 2009 to April 2011 at 13 centers
and randomly assigned 1:1 to receive oral aspirin with or without cilostazol.
The primary end point was 12-month angiographic restenosis of $50%.
Secondary end points were restenosis rates on duplex ultrasound imaging
(peak systolic velocity >200 cm/s), rates of major adverse cardiac events,
and target lesion event-free survival. End points were assessed in a blinded
fashion. The mean lesion length and reference vessel diameter at the treated
segment were 128 6 86 mm and 5.4 6 1.4 mm, respectively. Frequency of
stent use was similar between groups (88% vs 90% in the cilostazol and non-
cilostazol groups, respectively; P ¼ .82). Eleven patients died, and 152
(80%) had evaluable angiographic data at 12 months of follow-up. Angio-
graphic restenosis at 12 months was 20% (15 of 75) in the cilostazol group
vs 49% (38 of 77) in the noncilostazol group (P ¼ .0001) by intention-to-
treat analysis. There was also a signiﬁcantly higher event-free survival in the
cilostazol group at 12 months (83% vs 71%, P ¼ .02). Cardiovascular event
rates were similar in both groups.
Comment: The data indicate cilostazol, in combination with aspirin,
can signiﬁcantly reduce angiographic restenosis after endovascular therapy
for femoropopliteal disease. This study is limited by the fact that, strictly
speaking, the data apply only to a Japanese population. At the start of the
study, the S.M.A.R.T. stent was the only one available for this study.
Newer-generation stents and drug-eluting stents were not included.
Certainly, restenosis rates with the use of cilostazol and newer stents or clo-
pidogrel, or both, in more varied populations will also be of interest. Until
such data are available, routine addition of cilostazol as an adjunct to fem-
oropopliteal stenting is not likely to occur.
Home-Based Walking Exercise Intervention in Peripheral Artery
Disease a Randomized Clinical Trial
McDermott MM, Liu K, Guralnik JM, et al. JAMA 2013;310:57-65.
Conclusions: Home-based walking exercise programs can signiﬁ-
cantly improve walking endurance, physical activity, and patient-perceived
walking endurance and speed in patients with peripheral arterial disease
(PAD), with and without classic claudication symptoms.
Summary: Few patients with PAD participate in supervised treadmill
exercise therapy (Regensteiner JG, Curr Drug Targets Cardiovasc Haematol
Disord 2004;4:233-9). There may be many reasons why supervised exercise
therapy is not used in the PAD patient, including that it requires regular
transportation to an exercise center and that supervised exercise is not
generally covered by medical insurance. Although home-based walking
exercise would seem a promising alternative to supervised exercise, trials
have yielded conﬂicting results with respect to the efﬁcacy of home-based
exercise in the PAD patient. Indeed, most physicians do not recommend
home-based walking exercise to patients with PAD (Hirsch AT et al, Vasc
Med 2001;6:87-96; and McDermott MM et al, J Gen Intern Med
2002;17:895-904). Here, the authors report the result of the Group
Oriented Arterial Leg Study, a randomized, controlled, clinical trial
designed to assess if an intervention to increase home-based walking exercise
would improve walking performance at the 6-month follow-up in patients
with PAD. A group-mediated cognitive behavioral intervention incorpo-
rating group support and self-regulatory skills was used to help participants
adhere to a home-based exercise program. The authors’ hypothesis was that
the intervention group would have greater improvement in objective and
subjective measures of walking performance and physical activity compared
with a control group that received health education alone. The study
included 194 patients with PAD, 72.2% of whom did not have classic symp-
toms of intermittent claudication. The study took place in Chicago between
July 22, 2008, and December 14, 2012. Randomization was to one of two
parallel groups, a home-based group-mediated cognitive behavioral walking
intervention or an attention control condition. The primary outcome was
the 6-month change in 6-minute walk performance. The secondary
outcomes included the 6-month change in treadmill walking, physical
activity, Walking Impairment Questionnaire, and Physical and Mental1423
